Source: Acrofan

Immune-Onc: Immune-Onc Therapeutics to Present Encouraging Phase 1 Data for IO-108 at AACR Annual Meeting 2023

Read full article »
Immune-Onc's Competitors | Immune-Onc's News | Immune-Onc's Financials
Stay up-to-date with the latest news on Immune-Onc
Est. Annual Revenue
$5.0-25M
Est. Employees
1-25
Charlene Liao's photo - President & CEO of Immune-Onc

President & CEO

Charlene Liao

CEO Approval Rating

90/100

Read more
Stay up-to-date with the latest news on Immune-Onc